.jpeg)
2026-07-20 07:28:12
Capivasertib is an oral AKT inhibitor with molecular formula C₂₁H₂₅ClN₆O₂, selectively binding to AKT protein to block PI3K/AKT signaling, used in precision therapy for breast cancer and other tumors.
2026-07-20 07:25:47
Avatrombopag is an oral thrombopoietin receptor agonist indicated for chronic liver disease-associated thrombocytopenia and chronic immune thrombocytopenia (ITP) in adults and children aged 1 year and older, promoting platelet production via bone marrow stimulation.
2026-07-20 07:22:46
Capivasertib is an oral AKT inhibitor used to treat breast cancer and prostate cancer. This article compares the original brand and generic versions from Laos, highlighting differences in price, composition, and considerations for selection.
2026-07-20 07:19:23
Gilteritinib is an oral FLT3 inhibitor specifically indicated for adult patients with FLT3 mutation-positive relapsed or refractory acute myeloid leukemia (AML), precisely blocking abnormal signaling pathways to achieve targeted treatment.
2026-07-17 07:15:40
Learn how Macitentan (Opsumit) fits into PAH management. This guide covers dietary compatibility, critical warnings against St. John’s Wort, drug-drug interactions, and mandatory contraception requirements.
2026-07-17 07:10:28
This article analyzes the 2026 FDA approval of Selumetinib for adult Neurofibromatosis Type 1 (NF1) with symptomatic plexiform neurofibromas (PN). Covering KOMET Phase III data, BSA-based dosing, hepatic impairment adjustments, and global market availability, it serves as a comprehensive guide for clinicians.
2026-07-16 07:37:00
This guide details the essential baseline evaluations and proactive management strategies for patients starting Lenvatinib therapy. It covers hypertension, proteinuria, hypothyroidism, hand-foot skin reactions, cardiac monitoring, and drug interactions.
2026-07-16 07:21:04
This article summarizes adverse reactions associated with donidalorsen (DAWNZERA®) for prophylaxis of hereditary angioedema (HAE) attacks in patients aged 12 and older, including injection site reactions, upper respiratory tract infection, urinary tract infection, abdominal discomfort, hypersensitivity reactions, and monitoring of platelet/liver function, with safety notes for patients and clinicians.
2026-07-15 07:25:49
This guide provides global patients with comprehensive information on Inluriyo, covering its active ingredient, mechanism of action, eligible population, dosing guidelines, and safety precautions.
2026-07-14 05:31:14
Idelalisib is an oral PI3Kδ inhibitor indicated for relapsed/refractory chronic lymphocytic leukemia (CLL), follicular lymphoma (FL), and small lymphocytic lymphoma (SLL). The recommended dose is 150 mg twice daily. Close monitoring for severe hepatic, pulmonary, and intestinal toxicities, as well as life-threatening diarrhea, is required. This article covers indications, dosing, warnings, and adverse reactions.
2026-07-14 05:26:41
Lorlatinib is an oral tyrosine kinase inhibitor indicated for ALK-positive advanced non-small cell lung cancer (NSCLC). The recommended dose is 100 mg once daily. Treatment must be initiated by a physician experienced in anticancer therapy and preceded by ALK genetic testing. This article covers dosing, mechanism of action, common side effects, and key contraindications.
2026-07-14 05:23:09
Elafibranor is approved for adult patients with primary biliary cholangitis (PBC), used either in combination with ursodeoxycholic acid (UDCA) for those with inadequate response, or as monotherapy for those intolerant to UDCA. The recommended dose is 80 mg once daily orally. No dose adjustment is needed for elderly or renally impaired patients, but use is not recommended in severe hepatic impairment. This summary covers dosing, special population considerations, warnings, and adverse reactions.
